NAGA-GROUP-AG
13.1.2022 15:24:10 CET | Business Wire | Press release
NAGA Group AG (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for trading, cryptocurrencies and payments NAGA.com, has exceeded its revenue guidance for 2021 according to unaudited preliminary figures.
Consolidated group revenue more than doubled to around EUR 55.3 million compared to previous year (2020: EUR 24.4 million). The strong growth is underlined by a record EBITDA of EUR 12.8 million, which is also almost a doubling compared to 2020 (EUR 6.6 million). Furthermore, NAGA reports that over 277,000 new accounts joined its trading platform, a 128% increase compared to last year (2020: 122,000 new accounts).
Traded volume in 2021 reached EUR 250 billion for the first time, which means that the company was also able to double this metric compared to 2020 (EUR 121 billion). In addition, NAGA executed more than 10 million real-money transactions, an increase of 60% compared to 2020 (6.3 million). Notably, the strongest growth metric is the copy-trading activity. In 2021 NAGA saw over 4.8 million trades copied via its unique Auto Copy tool, that is almost tripling compared to 2020 (1.7 million copied trades).
"2021 was a fantastic year for NAGA. We have delivered another record year and achieved several milestones along the way. The investments in growth and the continuous acceleration of our marketing activities have paid off. Additionally, we have launched great products such as NAGA Pay, improved our platform and welcomed strategic investors to our cap table. 2022 will be another eventful year. We expect to be among the fastest growing neo-brokers, by gaining further market share in existing markets but also by expanding into new markets, while also increasingly focusing on the crypto and DeFi space with our brand-new platform NAGAX", comments Benjamin Bilski, Founder and CEO of NAGA.
Launch of NAGAX in Q1 2022
NAGA announces the launch of a brand-new social trading platform focused on cryptocurrencies: NAGAX,
The platform aims to offer:
- A unique Web3 social trading experience
- A spot exchange supporting over 700 tradable assets
- A futures and derivatives exchange
- A crypto-currency wallet with top level security
- An inbuilt NFT platform
- A staking platform
- A launchpad for promising projects
- Educational video content in the Learn-platform against rewards
The platform will offer a globally unique "Web3 Social Investing Feed" which automatically converts each user generated content on the platform into an NFT that can be monetized.
"With NAGA we have built one of the most innovative brokerage platforms in the industry - driven by social interaction and ultimately copy trading. Also, we gained unique insights between content creators and influencers and their needs. However, we believe that Decentralized Finance (DeFi) will be one of the strongest growing segments in the financial space and therefore will combine our knowledge with all our innovation capabilities and breadth of experience. With our brand new Web3 Social Investing Feed we believe to set a new standard in the world of financial influencers, improving their capabilities to serve their audience better, while offering instant monetisation of their content bypassing the middleman", says Bilski .
He also adds: "A financial influencer, for example, who offers premium content such as trading signals or technical analysis, posts the content and can directly set a price and availability. The post is automatically converted to an NFT. Any user who has access to an Ethereum-based wallet can unlock the content immediately. Each content is thus tokenized and can even be traded as an NFT itself. And of course, NAGAX will offer traders the opportunity to copy influencers' crypto trades for more than 700 assets via the social feed. The crypto world is highly fragmented. Crypto traders are literally forced to follow and join multiple groups and accounts across different platforms in order not to miss out. Crypto influencers, on the other hand, have to manage a wide variety of channels and monetization streams. Hence, we believe that our concept of content, direct monetization for influencers and copy trading on cryptocurrencies will experience great demand and will create a strong new source of revenue for NAGA."
The first version of NAGAX will launch within Q1 2022.
NAGAs CEO Benjamin Bilski will hold a recorded webinar on Friday the 14th of January at 15:00 (CET) and present NAGAX in detail. To join please visit https://naga.com/academy/webinars/936
###
About NAGA
NAGA is an innovative fintech company that has developed a socially enhanced financial system that creates a unified and seamless experience across personal finance and investing. Its proprietary platform offers a range of products ranging from trading, investing, and cryptocurrencies to a physical VISA card and social investing features such as a Feed, a Messenger and Auto-Copy. NAGA is a synergistic all-in-one solution that's accessible and inclusive, and that provides a better way to trade, invest, connect, earn, acquire and pay, across both fiat and crypto.
| Language: | English |
| Company: | The NAGA Group AG |
| Hohe Bleichen 12 | |
| 20354 Hamburg | |
| Germany | |
| E-mail: | info@naga.com |
| Internet: | www.naga.com |
| ISIN: | DE000A161NR7 |
| WKN: | A161NR |
| Indices: | Scale 30 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005574/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom